OXB Stock Overview
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Oxford Biomedica plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£4.13 |
| 52 Week High | UK£4.50 |
| 52 Week Low | UK£1.64 |
| Beta | 1.05 |
| 11 Month Change | -0.60% |
| 3 Month Change | 19.05% |
| 1 Year Change | 120.59% |
| 33 Year Change | -69.44% |
| 5 Year Change | -26.73% |
| Change since IPO | -83.66% |
Recent News & Updates
Recent updates
Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?
Oct 19
Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%
Aug 23Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 15Is Oxford Biomedica (LON:OXB) Using Too Much Debt?
Oct 06Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings
May 02We're Not Worried About Oxford Biomedica's (LON:OXB) Cash Burn
Jun 29Shareholder Returns
| OXB | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -1.4% | -4.0% | 0.7% |
| 1Y | 120.6% | -18.9% | 6.1% |
Return vs Industry: OXB exceeded the UK Biotechs industry which returned -19.8% over the past year.
Return vs Market: OXB exceeded the UK Market which returned 6.3% over the past year.
Price Volatility
| OXB volatility | |
|---|---|
| OXB Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: OXB has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: OXB's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 834 | Frank Mathias | www.oxb.com |
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product.
Oxford Biomedica plc Fundamentals Summary
| OXB fundamental statistics | |
|---|---|
| Market cap | UK£434.61m |
| Earnings (TTM) | -UK£142.02m |
| Revenue (TTM) | UK£97.28m |
4.5x
P/S Ratio-3.1x
P/E RatioIs OXB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OXB income statement (TTM) | |
|---|---|
| Revenue | UK£97.28m |
| Cost of Revenue | UK£61.54m |
| Gross Profit | UK£35.74m |
| Other Expenses | UK£177.76m |
| Earnings | -UK£142.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.35 |
| Gross Margin | 36.74% |
| Net Profit Margin | -145.98% |
| Debt/Equity Ratio | 55.8% |
How did OXB perform over the long term?
See historical performance and comparison